Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma

T Cell Non-Hodgkin Lymphoma Clinical Trial

Official title: A Pilot Study of Gleevec (Imatinib Mesylate) in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma

Status Completed

Clinical Trial Summary

The purpose of this research study is to evaluate the overall response rate to imatinib mesylate in participants with relapsed or refractory T cell non-Hodgkin's lymphoma. This drug has been used in chronic myeloid leukemia and information from those other research studies suggests that it may help to treat T cell non-Hodgkin's lymphoma.

Clinical Trial Description

• Participants will take the study drug orally each day of each eight week treatment cycle.

• During all treatment cycles, participants will have a physical exam and will be asked questions about their general health and specific questions about any problems they might be having and any medications they may be taking.

• If the participant has skin lesion, photographs will be taken of the skin lesion to assess the response of the tumor to study treatment. CT scans will be used to follow the participants response to treatment.

• Blood tests, including chemistry, hematology, and other tests to measure any additional effect of the study drug and disease status will also be performed. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, Non-Hodgkin
• Lymphoma, T-Cell
• T Cell Non-Hodgkin Lymphoma

• NCT number: NCT00684411
• Study type: Interventional
• Source: Dana-Farber Cancer Institute
• Status: Completed
• Phase: N/A
• Start date: June 2008
• Completion date: August 2014